Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2014-09-11 / Front Oncol 2014;4:224Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen /von 2014-05-13 / Cytotherapy 2014 Jul;16(7):946-64Wilms‘ tumor gene 1 immunotherapy in pelvic gynecological malignancies
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Ovarian Cancer, Uterine Cancer /von 2014-05-02 / Expert Rev Clin Immunol 2014 Jun;10(6):705-11Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function
/in Colorectal Cancer, Dendritic Cells, International Publications, IOZK Veröffentlichungen /von 2014-01-01 / Expert Rev Vaccines 2014 Jan;13(1):117-30Myeloid-derived suppressor cells in glioma
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2013-11-12 / Expert Rev Neurother 2013 Dec;13(12):1395-406Dendritic cell-based immunotherapy in ovarian cancer
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Ovarian Cancer /von 2013-11-06 / Oncoimmunology 2013 Dec;2(12):e27059Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2013-10-01 / Immunotherapy 2013 Oct;5(10):1043-6Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Ovarian Cancer /von 2013-09-01 / Anticancer Res. 2013 Sep;33(9):3855-9
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution